ImClone Systems Incorporated is a biopharmaceutical firm dedicated to the development of biological medicines in the area of oncology. The company utilizes advances in the fields of molecular biology, oncology, genomics and antibody engineering to generate product candidates designed to address specific genetic mechanisms involved in cancer growth and development. ImClone Systems' goal is to become a fully integrated biopharmaceutical organization with the capabilities and resources to transition compounds from the research and development stage through to commercial manufacture, marketing and sales. The company's research and development programs include growth factor blockers and angiogenesis inhibitors. ImClone Systesms was established in 1984 and has corporate and scientific offices in New York and Branchburg, N.J.
Partial Data by Infogroup (c) 2024. All rights reserved.